Corrigendum to “Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 201 (2024) 104416]

IF 5.5 2区医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2024-08-10 DOI:10.1016/j.critrevonc.2024.104466

Joel Veas Rodríguez , Ana Prieto , Ester Vilaprinyo , Marta Bonet , Marc Diez , Antonieta Salud , Robert Montal

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

晚期胃食管癌 III 期随机试验中的替代终点：Crit. Rev. Oncol./Hematol. 201 (2024) 104416]的更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.

期刊最新文献

Editorial Board Erratum to “Unleashing precision: A review of targeted approaches in pleural mesothelioma” [Crit. Rev. Oncol./Hematol. 203C (2024) 104481] Corrigendum to “The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?” [Crit. Rev. Oncol./Hematol. 204 (2024) 104515] Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404] Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527]